TKIs (EGFR VEGF BTK etc.)

Delve into the world of TKIs (EGFR VEGF BTK etc.) in China’s pharmaceutical industry. Fineline Info & Tech provides reliable data, news, and insights on TKIs (EGFR VEGF BTK etc.) to help you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

CSPC's Recombinant Herpes Zoster Vaccine SYS6052 Clears U.S. FDA IND – Company's First Recombinant Protein Vaccine Candidate to Enter Clinical Trials
CompanyDrug

CSPC’s Recombinant Herpes Zoster Vaccine SYS6052 Clears U.S. FDA IND – Company’s First Recombinant Protein Vaccine Candidate to Enter Clinical Trials

CSPC Pharmaceutical Group Limited (HKG: 1093) announced that its Class 1 innovative drug, a recombinant herpes zoster vaccine (SYS6052), has received IND approval from the U.S. FDA to initiate clinical…

China's CDE Launches "Pioneer Plan" Pilot to Advance New Approach Methodologies (NAMs) in Non‑Clinical Drug Evaluation – Aiming to Reduce, Refine, and Replace Animal Testing

China’s CDE Launches “Pioneer Plan” Pilot to Advance New Approach Methodologies (NAMs) in Non‑Clinical Drug Evaluation – Aiming to Reduce, Refine, and Replace Animal Testing

GenFleet's Oral KRAS G12D Inhibitor GFH375 Wins Third NMPA Breakthrough Therapy Designation – Combination with Cetuximab for Pretreated Metastatic Colorectal Cancer

GenFleet’s Oral KRAS G12D Inhibitor GFH375 Wins Third NMPA Breakthrough Therapy Designation – Combination with Cetuximab for Pretreated Metastatic Colorectal Cancer

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

Allist Pharmaceuticals Receives NMPA Approval for Furmonertinib in Exon 20 Insertion NSCLC

CompanyDrug

Alphamab Oncology Doses First Patient in KN046-209 Study for NSCLC

CompanyDrug

Roche’s Rozlytrek Wins NMPA Approval for ROS1+ NSCLC Treatment

CompanyDrug

InnoCare Pharma’s Orelabrutinib sNDA Accepted for Marginal Zone Lymphoma

CompanyDrug

HutchMed and AstraZeneca’s Tagrisso-Orpathys Combo Shows Promise in NSCLC Study

CompanyDrug

Inmagene and HutchMed Dose First Subject in IMG-004 Phase I Study

CompanyDrug

Dizal Pharma’s Sunvozertinib Shows Promise in NSCLC with EGFR Exon 20 Insertion

CompanyDrug

HutchMed’s FRESCO-2 Study for Elunate in Colorectal Cancer Meets Primary Endpoint

Show More